Skip to main content

Home/ Medicine & Healthcare/ Group items tagged aldara

Rss Feed Group items tagged

avivajazz  jazzaviva

Efficacy of Aldara® (Imiquimod) for Treatment of Low-Risk Nodular Basal Cell ... - 0 views

  •  
    Aldara® can eradicate 64% of low-risk nodular basal cell carcinomas.
avivajazz  jazzaviva

Imiquimod cream (Aldara) for superficial basal cell carcinoma: NPS - Better choices, Be... - 0 views

  •  
    Imiquimod cream (Aldara) for superficial basal cell carcinoma
avivajazz  jazzaviva

Aldara ~ Prior Authorization Guideline - 0 views

  •  
    Superficial Basal Cell Carcinoma Aldara™ cream is indicated for the topical treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults, with a maximum tumor diameter of 2.0 cm, located on the trunk (excluding anogenital skin), neck, extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured.  The histological diagnosis of superficial basal cell carcinoma should be established for other types of basal cell carcinomas, including nodular, morpheaform (fibrosing or sclerosing) types.
avivajazz  jazzaviva

Mohs surgery in sBCC following treatment with imiquimod 5% cream - 0 views

  •  
    Eight of nine individuals, 89% (95% CI 56% to 97%) were histologically clear of sBCC at 52 weeks.
avivajazz  jazzaviva

Aldara (tm) [imiquimod] Cream ~ Full Prescribing Information ~ FDA / Package Insert - 0 views

  •  
    FDA-approval:  * Biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults; maximum tumor diameter of 2.0 cm on trunk, neck, or extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured (1.2)
avivajazz  jazzaviva

Recurrence rate of superficial basal cell carcinom... [Eur J Dermatol. 2008 Nov-Dec] - ... - 0 views

  •  
    The estimate of overall treatment success for all treated patients at the end of follow-up was 77.9% (80.9% considering histology). The data support clinical assessment of initial response as predictive of long-term outcome. Most of the recurrences occurred early, indicating that careful follow-up is important during the first year after treatment.
avivajazz  jazzaviva

Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod ... - 0 views

  •  
    Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. by Harald Gollnick
1 - 20 of 52 Next › Last »
Showing 20 items per page